About the Campaign Engage in Global Biosimilars Week

IGBA member companies are the pioneers and global leaders in the development and marketing of biosimilar medicines. Global Biosimilars Week is a time to engage in a globally aligned educational initiative to raise awareness of biosimilar medicines. Through daily themes, we encourage you to share resources about the value of biosimilars: biosimilar basics, regulation, benefits, clinical use and market adoption as well as future opportunities for patients, healthcare professionals and healthcare system.

VIEW MEMBER ASSOCIATIONS

Over

300

Biosimilar Approvals*

*Approvals in jurisdictions of IGBA membership as of 20 October 2020

Over

10

Therapeutic Areas Covered*

*Approvals in jurisdictions of IGBA membership as of 20 October 2020

 

 

Biosimilar Basics The Basics of Biosimilar Medicines

Biosimilars are biological medicines that are highly similar to an already-approved originator biological medicine, with no meaningful differences in efficacy and safety. Biological medicines, including biosimilars, are often large and complex molecules that are made from living cells using biotechnology. They are used to treat diseases such as diabetes, inflammatory diseases and cancer. Examples of biosimilar medicines include:

  • Proteins such as insulin and growth hormones
  • Larger and more complex proteins such as monoclonal antibodies

View More Basics

 

 

Biosimilar Approvals Approval of Biosimilars Worldwide

Biosimilars are approved after rigorous scientific evaluation by regulators. They are manufactured to the same regulatory standards as originator biological medicines.

  • No biological medicines are strictly “identical” to themselves batch to batch, and patients and prescribers have years of experience taking ‘non-identical’ highly similar versions of the originator reference product. This same scientific principle used to manage variability of the reference biological product is applied to evaluating and approving biosimilars. Stakeholders should have trust and confidence in the regulatory agencies that approve both the reference product and the biosimilar medicine.
  • Regulatory authorities globally have confirmed biosimilars to be “highly similar to the originator in quality and biological activity, with no clinically meaningful differences in efficacy, safety and immunogenicity.”

View IGBA Resource

 

 

Benefits of Biosimilars Value of Biosimilars for Patients, Healthcare Professionals and Healthcare System

Biosimilars can provide alternative treatment options for existing standards of care in several disease areas, creating enhanced availability and access to biologic medicines. Biosimilars create cost competition that benefit patients, healthcare professionals and healthcare systems.

  • According to a 2017 study, the availability of biosimilar medicines could increase patient access to biologic therapy overall to more than a million additional patients. Read More

View Patient Story

 

 

Clinical Use and Market Adoption Vast Experience with Biosimilar Medicines

Trust and confidence in biosimilar medicines has grown steadily along with clinical experience. Governments and payers around the world have adopted policies featuring newly created incentives for increased biosimilars development and adoption in the clinical practice. Millions of people around the world can live longer, healthier lives thanks to greater access to biologic therapies, including biosimilars.

Biosimilars in the EU. Information guide

 

 

Future Opportunities What’s next?

Ensuring continued benefit of biosimilars for patient access to biologic medicines and health system sustainability is dependent on the decisions made today. While biosimilar regulatory approvals have increased globally, biosimilar medicines still face uptake challenges in many countries. Increasing biosimilar availability could provide significant value for health care systems, enabling resources to be re-invested where most needed by patients, health care professionals and healthcare systems. Opportunities to share information across borders, like Global Biosimilars Week, can spread real world experience with the clinical use of biosimilar medicines to help identify the key enablers for patients, medical professionals, policymakers and other healthcare stakeholders to foster greater adoption of biosimilar medicines.

What you can do now?

#globalbiosimilarsweek

 

 

Social Media Toolkit #globalbiosimilarsweek

DOWNLOAD SOCIAL MEDIA TOOLKIT

GLOBAL BIOSIMILARS WEEK Resources

 

 

IGBA Member Associations

777 Sixth Street, NW, Suite 510. Washington, DC 20001
Tel: +1 202-249-7100
Fax: +1 202-249-7105

media@gphaonline.org
accessiblemeds.org

601 New Jersey Ave NW, Suite 850. Washington DC 20001. 202.249.7100

biosimilarscouncil.org

4100 Yonge Street, Suite 501 Toronto, Ontario M2P 2B5 Canada
Tel.: +1 (416) 223-2333
Fax: +1 (416) 223-2425

info@canadiangenerics.ca
www.canadiangenerics.ca

4100 Yonge Street, Suite 501
Toronto, Ontario  M2P 2B5 Canada

Tel. : (416) 223-2333
Fax : (416) 223-2425

info@biosimilarscanada.ca
www.biosimilarscanada.ca

PO Box 87
Deakin West ACT 2600

www.gbma.com.au

Rue d’Arlon, 50
B-1000 Brussels, Belgium
Tel: +32 (0)2 736 84 11
Fax: +32 (0)2 736 74 38

info@medicinesforeurope.com
www.medicinesforeurope.com

Rue d’Arlon, 50
B-1000 Brussels, Belgium
Tel: +32 (0)2 736 84 11
Fax: +32 (0)2 736 74 38

info@medicinesforeurope.com
www.medicinesforeurope.com

Viaducto Miguel Alemán No. 193-2. Col. Escandón. C.P. 11800 – México, D.F.
Tel. +52 55 5482 9000
Mobile  55 5216 1727

contacto@amegi.com.mx
www.amegi.com.mx

Av. del Libertador 602 – Piso 6 (C1001ABT)
Ciudad Autónoma de Buenos Aires – Argentina
Tel: 4819-9550 (L.R.)

info@cilfa.org.ar
www.cilfa.org.ar

1342 Howick Mews, Waterfall Park, Bekker Rd, Midrand. PO Box 32361, Kyalami, 1684
Tel: +27 (0)11 3126966
Fax: +27 (0)86 5294245

info@napm.co.za
gbmsa.org

A-205 Sangam, 14B S V Road,
Santacruz West, Mumbai 400054.
T: +91-22-2610 9281

ipa-india.org

Khalda, Yazan Aranki Street, villa no.1 behind the Montessori Schools. P.O. Box 5382 Amman, 11953 Jordan
Tel: +962 6 541-3114
Fax: +962 6 541-3116

info@japm.com
www.japm.com

103-0023. 3-3-4, Nihonbashi honcho, Chuo-ku, Tokyo, 103-0023, Japan
Tel: +81 3-3279-1890
Fax: +81 3-3241-2978

www.jga.gr.jp

Global Business & Convention Centre. Mezzanine floor, block a,. No. 8, Jalan 19/1, section 19, 46300 Petaling Jaya. Selangor Darul Ehsan, Malaysia
Tel: +603-7931 9003
Fax : +603-7932 2730

www.mopi.org.my

P.O. Box 2665 Riyadh 11461 KSA
Tel: 00966 11 2687999
Mob: 00966 555498597

info@ncpi.org.sa
www.ncpi.org.sa

Rua Alvorada, 1280
CEP : 04550-004
São Paulo – SP
Tel: +55 (11) 3897-9767
Fax: +55 (11) 3845-0742

progenericos@progenericos.org.br
www.progenericos.org.br

Fl. 5, No. 32-1, Songjiang Rd., Taipei City 104, Taiwan
Tel: +886 2-25314389
Fax: +886 2-25371389

contact@tgpa.org.tw
www.tgpa.org.tw

LEAVE MESSAGE Contact Us

GENERAL ENQUIRYCANADAEUROPEU.S.A.